Carcinoid heart disease
diseaseOn this page
Also known as carcinoid heart diseasesheart disease, carcinoidheart diseases, carcinoid
Summary
Carcinoid heart disease (MONDO:0043529) is a disease and 5 clinical trials. Top therapeutic interventions include telotristat ethyl, lanreotide, and lutetium oxodotreotide lu-177. A subtype of heart disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | carcinoid heart disease |
| Mondo ID | MONDO:0043529 |
| MeSH | D002275 |
| SNOMED CT | 36222008 |
| UMLS | C0007093 |
| MedGen | 762 |
| Is cancer (heuristic) | no |
Also known as: carcinoid heart disease · carcinoid heart diseases · heart disease, carcinoid · heart diseases, carcinoid
Disease family
This is a subtype of heart disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › carcinoid heart disease
Related subtypes (33): endocardium disorder, pericardium disorder, cardiac tuberculosis, heart conduction disease, hypertensive heart disease, heart valve disorder, cardiomyopathy, coronary artery disorder, heart failure, congenital heart disease, heart aneurysm, rheumatic heart disease, cardiac rhythm disease, white forelock with malformations, atrioventricular defect-blepharophimosis-radial and anal defect syndrome, microcephaly-cardiac defect-lung malsegmentation syndrome, PHACE syndrome, microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type, cardiac anomalies-heterotaxy syndrome, polyvalvular heart disease syndrome, Thomas syndrome, 22q11.2 deletion syndrome, myocardial rupture, heart neoplasm, aortopulmonary window, cor biloculare, inflammation of heart layer, myocardial disorder, omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome, coronary microvascular disorder, cardiac ventricle disorder, cardiogenetic disease, cardiogenic shock
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Lanreotide | Phase 3 (in late-stage trials) |
| Telotristat Ethyl | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04065165 | PHASE3 | WITHDRAWN | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome |
| NCT04039516 | PHASE2 | UNKNOWN | Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy |
| NCT03498040 | Not specified | ACTIVE_NOT_RECRUITING | Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors |
| NCT05064514 | Not specified | ACTIVE_NOT_RECRUITING | Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease |
| NCT07450287 | Not specified | NOT_YET_RECRUITING | CardioNETPOL National Registry of Carcinoid Heart Disease |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TELOTRISTAT ETHYL | 4 | 2 |
| LANREOTIDE | 4 | 1 |
| LUTETIUM OXODOTREOTIDE LU-177 | 4 | 1 |